Biosimilars – Forecast – Respiratory
In 2024, sales of branded biologics for respiratory indications totaled $7 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout the 2024-2034 forecast period, biosimilars are expected to enter the market and erode patient share and drug prices. We present our forecasts for key reference brands and their biosimilars by molecule and country / region.
Table of contents
Related Market Assessment Reports
Report
Systemic Lupus Erythematosus – Unmet Need – Unmet Need – Moderate to Severe Systemic Lupus Erythematosus (US/EU)
Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect different organ systems of the body and manifest in a wide range of clinical symptoms, from general fatigue to serious…
Report
Systemic Lupus Erythematosus | Unmet Need | Moderate to Severe Systemic Lupus Erythematosus | US/EU | 2024
Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect different organ systems of the body and manifest in a wide range of clinical symptoms, from general fatigue to serious…
Report
Dry and Wet Age-Related Macular Degeneration – Landscape & Forecast – Disease Landscape & Forecast (G7)
AMD is a leading cause of vision loss across the G7 markets, with wet AMD accounting for most drug-treated cases. The market is dominated by IVT therapies such as Avastin, Eylea, Vabysmo, and Eylea…
